At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Lipoic Acid plus Omega-3 Fatty Acids +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study: Lipoic Acid and Omega-3 Fatty Acid for Alzheimer's Disease Prevention
In Brief
A Phase 2 clinical trial evaluating Lipoic Acid plus Omega-3 Fatty Acids and Placebo for Treated Hypertension. Completed, enrolled 42 participants across 2 sites.
Detailed Summary
The primary aim of the pilot study is to provide data that can be used to better determine sample size for the design of a larger clinical trial. The pilot will evaluate the effectiveness of Lipoic Acid (LA) plus Omega-3 fatty acids (Omega-3) on preventing Alzheimer's Disease (AD). The investigators will also collect data to evaluate recruitment rate, safety, and compliance over the 12 month study period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreated Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartApr 2013
Primary CompletionOct 2015
TodayJul 2026
First PostedJan 31, 2013
Enrollment StartApr 1, 2013
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.4 years ago
Interventions
Lipoic Acid plus Omega-3 Fatty Acidsdrug
alpha lipoic acid (racemic) and fish oil concentrate
Placebodrug
placebo capsules